← Leaderboards
Robert A Gross
University Of Pennsylvania
$437,591
Attributed
$437,591
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$437,591 · 5
By mechanism
M01$437,591 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Ian Frank$25,757,892
- Robert Gross$16,941,227
- Rob R Macgregor$4,980,820
- Harvey Michael Friedman$28,257,678
- David S Metzger$45,509,531
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationAids TherapyPatient Oriented ResearchHiv InfectionsCombination ChemotherapyVirus LoadAntiaids AgentTherapy ComplianceSelf CareAidsVirus RnaAmprenavirBehavioral /Social Science Research TagDrug Administration Rate /DurationDrug ResistanceDrug Screening /EvaluationEfavirenzHuman Immunodeficiency Virus 1NelfinavirProtease Inhibitor
Grant awards (6)
ADHERENCE TO PROTEASE INHIBITORS IN HIV-EFAVIRENZ (LONG TERM)$64,912
M01 · FY2005 · RR
TWICE DAILY AND ONCE DAILY POETNET ANTIRETROVIRAL THERAPY IN HIV SUBJECTS$24,540
M01 · FY2005 · RR
Adherence to Protease Inhibitors in HIV-Efavirenz (Long Term)$336,282
M01 · FY2004 · RR
PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS FOR FAILURE$5,929
M01 · FY2004 · RR
SELF-ADMINISTERED THERAPY AND THERAPY ADMINISTERED UNDER DIRECT OBSERVATION$3,387
M01 · FY2004 · RR
VIROLOGIC TREATMENT FAILURE$2,541
M01 · FY2004 · RR